(0.33%) 5 116.91 points
(0.30%) 38 355 points
(0.37%) 15 987 points
(-0.87%) $83.12
(5.77%) $2.03
(0.46%) $2 357.90
(0.47%) $27.67
(3.92%) $958.25
(-0.22%) $0.933
(-0.38%) $10.98
(-0.54%) $0.796
(1.66%) $93.40
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 6.85%
@ $3.65
発行日: 14 2月 2024 @ 23:30
リターン: -24.29%
前回のシグナル: 2月 13 - 05:55
前回のシグナル:
リターン: -6.48 %
Live Chart Being Loaded With Signals
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases...
Stats | |
---|---|
本日の出来高 | 522 505 |
平均出来高 | 1.70M |
時価総額 | 401.18M |
EPS | $0 ( 2024-02-14 ) |
次の収益日 | ( $-0.350 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.770 |
ATR14 | $0.00400 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Neupert Peter M | Buy | 15 000 | Common Stock |
2024-03-12 | Neupert Peter M | Sell | 15 000 | Stock Option (right to buy) |
2024-03-04 | Pellini Michael J | Buy | 31 328 | Common Stock |
2024-03-04 | Pellini Michael J | Buy | 48 044 | Stock Option (right to buy) |
2024-03-04 | Owen Katey Einterz | Buy | 31 328 | Common Stock |
INSIDER POWER |
---|
61.58 |
Last 100 transactions |
Buy: 4 473 782 | Sell: 1 037 795 |
ボリューム 相関
Adaptive Biotechnologies 相関
10 最も負の相関 | |
---|---|
SKYA | -0.953 |
HERA | -0.948 |
BRIV | -0.942 |
LDHA | -0.94 |
AGGR | -0.939 |
HERAU | -0.939 |
ISEE | -0.939 |
CRZN | -0.938 |
TBSAU | -0.938 |
PRSR | -0.937 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Adaptive Biotechnologies 相関 - 通貨/商品
Adaptive Biotechnologies 財務諸表
Annual | 2023 |
収益: | $170.28M |
総利益: | $72.49M (42.57 %) |
EPS: | $-1.560 |
FY | 2023 |
収益: | $170.28M |
総利益: | $72.49M (42.57 %) |
EPS: | $-1.560 |
FY | 2022 |
収益: | $185.31M |
総利益: | $127.40M (68.75 %) |
EPS: | $-1.000 |
FY | 2021 |
収益: | $154.34M |
総利益: | $105.04M (68.06 %) |
EPS: | $-1.580 |
Financial Reports:
No articles found.
Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。